These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 9815559)

  • 1. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
    van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
    Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
    van Acker FA; Boven E; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
    Clin Cancer Res; 2001 May; 7(5):1378-84. PubMed ID: 11350909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
    Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week.
    van Acker FA; van Acker SA; Kramer K; Haenen GR; Bast A; van der Vijgh WJ
    Clin Cancer Res; 2000 Apr; 6(4):1337-41. PubMed ID: 10778960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protectors against doxorubicin-induced cardiotoxicity: flavonoids.
    Bast A; Kaiserová H; den Hartog GJ; Haenen GR; van der Vijgh WJ
    Cell Biol Toxicol; 2007 Jan; 23(1):39-47. PubMed ID: 17063376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells.
    Abou El Hassan MA; Heijn M; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC
    Cancer Gene Ther; 2003 Apr; 10(4):270-7. PubMed ID: 12679799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice.
    Bruynzeel AM; Vormer-Bonne S; Bast A; Niessen HW; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):509-14. PubMed ID: 17177067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
    Bast A; Haenen GR; Bruynzeel AM; Van der Vijgh WJ
    Cardiovasc Toxicol; 2007; 7(2):154-9. PubMed ID: 17652822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.
    van Acker SA; Kramer K; Grimbergen JA; van den Berg DJ; van der Vijgh WJ; Bast A
    Br J Pharmacol; 1995 Aug; 115(7):1260-4. PubMed ID: 7582554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice.
    Abou El Hassan MA; Kedde MA; Zwiers UT; Bast A; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):306-10. PubMed ID: 12721758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
    Hoke EM; Maylock CA; Shacter E
    Free Radic Biol Med; 2005 Aug; 39(3):403-11. PubMed ID: 15993339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.
    van Acker SA; Voest EE; Beems DB; Madhuizen HT; de Jong J; Bast A; van der Vijgh WJ
    Cancer Res; 1993 Oct; 53(19):4603-7. PubMed ID: 8402634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
    Alderton P; Gross J; Green MD
    Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase.
    Kaiserová H; Simůnek T; van der Vijgh WJ; Bast A; Kvasnicková E
    Biochim Biophys Acta; 2007 Sep; 1772(9):1065-74. PubMed ID: 17572073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
    Jacobs H; Peters R; den Hartog GJ; van der Vijgh WJ; Bast A; Haenen GR
    Drug Metab Dispos; 2011 May; 39(5):750-6. PubMed ID: 21266594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiradical and chelating effects in flavonoid protection against silica-induced cell injury.
    Kostyuk VA; Potapovich AI
    Arch Biochem Biophys; 1998 Jul; 355(1):43-8. PubMed ID: 9647665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained protective effects of 7-monohydroxyethylrutoside in an in vivo model of cardiac ischemia-reperfusion.
    De Celle T; Heeringa P; Strzelecka AE; Bast A; Smits JF; Janssen BJ
    Eur J Pharmacol; 2004 Jun; 494(2-3):205-12. PubMed ID: 15212976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotective effects and mechanism of action of polyphenols extracted from propolis against doxorubicin toxicity.
    Alyane M; Kebsa LB; Boussenane H; Rouibah H; Lahouel M
    Pak J Pharm Sci; 2008 Jul; 21(3):201-9. PubMed ID: 18614413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of monohydroxyethylrutoside in healthy volunteers.
    Willems AM; Bruynzeel AM; Kedde MA; van Groeningen CJ; Bast A; van der Vijgh WJ
    Cancer Chemother Pharmacol; 2006 May; 57(5):678-84. PubMed ID: 16136309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.